secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fortrea Holdings Inc. (FTRE)
CIK:        0001965040
Form:       8-K
Filed at:   2024-06-04T23:59:59+00:00
Accession:  0001965040-24-000041
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fortrea completes divestiture of Endpoint Clinical and Patient Access to Arsenal for $295M plus $45M milestone
--------------------------------------------------------------------------------

- Final purchase price $295M paid at closing plus $45M upon achieving transition milestones.
- Net proceeds to be used to reduce a portion of Fortrea's overall debt.
- Sam Osman appointed CEO of the new entities; Ray Hill named chairman.
- Fortrea becomes a pure-play clinical CRO after the divestiture.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1965040/000196504024000041/0001965040-24-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1965040/000196504024000041/ftre-20240603.htm
  HTML page:      https://secwatch.observer/filing/0001965040-24-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer